{"id":"W2105932257","doi":"10.1093/neuonc/nou356","title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study","year":2015,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Merck KGaA","keywords":"Medicine; Temozolomide; Internal medicine; Tolerability; Hazard ratio; Clinical endpoint; Oncology; Chemoradiotherapy; Gastroenterology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Adverse effect; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002208033,0.001496173,0.003116949,0.0006638454,0.0003102503,0.000844712,0.000944543,0.001216228,0.00234609],"category_scores_gemma":[0.001946602,0.0008227336,0.001718192,0.0005112063,0.001198774,0.001172067,0.0004172706,0.002612256,0.0003972066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009962593,"about_ca_system_score_gemma":0.001377773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00101829,"about_ca_topic_score_gemma":0.002521451,"domain_scores_codex":[0.9990357,0.0005457574,0.00007045038,0.0001465338,0.0000740571,0.0001274938],"domain_scores_gemma":[0.9984649,0.000387878,0.0004476896,0.0001301193,0.00007386071,0.000495464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9555579,0.01926743,0.001737833,0.00024938,0.0009237736,0.00002216341,0.00004566375,0.0004215001,0.002996002,0.0000442244,0.0003712007,0.01836287],"study_design_scores_gemma":[0.8244505,0.1697901,0.003818797,0.00001784208,0.0005656724,0.00002722932,0.00001829298,0.0004796001,0.0004707755,0.00005669456,0.0002886363,0.00001586302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955633,0.001917599,0.0003499376,0.0002295706,0.0001218986,0.001022655,0.0002971448,0.00004516368,0.0004528792],"genre_scores_gemma":[0.9932054,0.001701116,0.001199722,0.0005827702,0.0002960419,0.001557004,0.000778735,0.00001815082,0.0006611014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003116949,"threshold_uncertainty_score":0.01167738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03371996017441568,"score_gpt":0.3346704156490075,"score_spread":0.3009504554745918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}